1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends

Engineered TCR and CAR Immunotherapeutics 2015

  • March 2015
  • 201 pages
  • La Merie Publishing
Report ID: 2783215

Summary

Table of Contents

Engineered TCR and CAR Immunotherapeutics 2015:
A comparative analysis of the landscape of and business opportunities with  TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & CTLs

The engineered T cell receptor (TCR) for targeting of intracellur targets not druggable by conventional antibody technologies, and specifically targeted engineered T cells are two of the most promising emerging technologies in immuno-oncology apart from immune checkpoint modulators. The relevance of TCR targeting and engineered T cells is reflected by impressive clinical results with CD19 chimeric antigen receptor (CAR) T cells and outstanding partnering and financing deals concluded within the last two years.

Leveraging the power of T cells by cellular and recombinant immunotherapeutics

- Intra-cellular Targets
- Cell surface targets
- Cellular
- TCR T Cells
- CAR T Cells

- (autologous/allogeneic)
- Recombinant
- Bispecific TCR-anti-CD3
- (e.g. ImmTACs)
- Bispecific antibodies (incl. anti-CD3)


This report "Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with  TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & DLIs" as of March 2015 brings you up-to-date regarding key players, key technologies, TCR and CAR immunotherapeutic projects, business deals and private and public financing rounds. The report analyzes the TCR and CAR immunotherapeutic pipelines and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of TCR and CAR immunotherapeutics in terms of partnering economic conditions, private financing rounds and (initial) public offerings with the resulting market capitalization of companies.

However, progress in clinical trials and supply of clinical grade batches reveals some major limitations which need to be surmounted and the problems solved if TCR and CAR immunotherapeutics want to become commercially viable and successful products. This report describes the challenges and limitations and identifies solutions provided by new technologies which offer tremendous business opportunities.

Download Sample Pages: Engineered TCR and CAR Immunotherapeutics 2015

This report has been built in a bottom-up basis by desktop search to identify and describe company, product, technology and business/financing profiles which then are evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities.

What will you find in the report?

- Profiles of TCR and CAR immunotherapeutics in development;
- Competitor analysis of CD19 CAR T cells;
- Options to improve CAR T cells regarding efficacy, safety, manufacturing and commercial value;
- Target analysis of TCR T cells in R&D;
- CAR T Cell pipeline in hematology;
- CAR T Cell pipeline in solid tumors;
- Allogeneic TCR and CAR T cells in R&D;
- Universal antibody-targeted CAR T cells and NK cells;
- Pipeline of most promising TILs, NK cells, DLIs and CTLs;
- Technologies needed for next generations of TCR and CAR immunotherapeutics;
- Profiles of biotechnology companies incl. financing and licensing/partnering;
- Profiles and scope of interest of Big Pharma/Biotech companies for TCRs & CARs;
- Stakeholder analysis (established, emerging, non-US, technology providing companies);
- Potential of alternative adoptive immunotherapies with NK cells, TILs, CTLs and DLIs;
- Analysis of major partnering deals between Big pharma and technology companies;
- Economic terms of pharma-biotech deals;
- Opportunities for biotech-biotech deals in the TCR and CAR field;
- Potential to raise private money with TCR and CAR technologies;
- Success in initial public offerings and follow on offerings with TCRs and CARs;
- Limitations and hurdles with current TCR and CAR immunotherapeutics;
- Opportunities for novel TCR and CAR immunotherapeutics;
- Pricing of TCR and CAR immunotherapeutics;
- Aspects of manufacturing and commercialization.


Who will benefit from the report?

- Venture capital, private equity and investment managers;
- Financial analysts;
- CFO;
- Business development and licensing (BDL) specialists;
- Marketing managers;
- CEO, COO and managing directors;
- Corporate strategy, product and portfolio analysts and managers;
- Chief Technology Officer;
- Cell technology and manufacturing specialists;
- Clinical and preclinical development specialists.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

CAR-T Disease Outlook [2017]

  • $ 8355
  • Industry report
  • June 2017
  • by Firstword Pharma

Will CAR-T cell therapies shape the treatment of blood cancers in the next decade? Anti-CD19 CAR-T cell therapies have demonstrated unprecedented response rates across patient subgroups of acute lymphocytic ...

Global CAR T Cell Therapy Market & Clinical Trials Insight 2022

  • $ 2400
  • Industry report
  • April 2017
  • by Kuick Research

“Global CAR T Cell Therapy Market & Clinical Trials Insight 2022” report highlights the ongoing clinical and non-clinical advancement in the field of Car T Cell Therapy. As per report findings, the ...

T-Cell Immunotherapy Market (2nd Edition), 2017-2030

  • $ 2499
  • Industry report
  • January 2017
  • by Roots Analysis Private Ltd.

INTRODUCTION The concept of immunotherapies dates back to the 18th century; however, since inception, the field has evolved tremendously and is currently cited as one of the most rapidly growing segments ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.